Evidence review · from the 250-topic plan
Wegovy vs compounded semaglutide: the $380-a-month question, argued both ways
The cash gap is exact: NovoCare's self-pay Wegovy runs about $499/month; the audited compounded floor runs $119 — a $380/month, $4,560/year difference for the same intended base molecule. What the $380 buys is real: FDA-verified identity, potency, sterility and batch consistency; the trial certificate itself; a factory dose-engineered pen that deletes vial math; and a supply chain with a regulator on it. What it doesn't buy is a different molecule or a different mechanism. This piece argues both sides at full strength, then hands you the four-question sorter — because this is the one comparison where “it depends” is the honest verdict, and the variables are yours.
The gap, itemized honestly
Both products intend the same base semaglutide at the same weekly logic. The brand adds: FDA review of the finished product, manufacturing under inspected consistency standards, the pen device, pharmacovigilance at national scale, and direct ownership of every trial number this site cites — STEP 1's 14.9%, SELECT's cardiovascular result, FLOW's kidney file. The compounded lane subtracts those certificates and $4,560 a year, adds a licensed-pharmacy provenance you can verify yourself, and hands you the syringe. Neither list is propaganda; both are the trade.
The case for the $499, at full strength
Certainty compounds in medicine. Every Wegovy pen is the audited object the trials studied — identity, potency and sterility verified by the process, not requested by the patient; the dose is engineered, not calculated; adverse-event reporting feeds a national system; and “is this batch right?” is a question you never think, which for many people is precisely what money is for. Add device preference (needle-phobic patients do better with pens), any history of a bad compounding experience, and situations where precision anxiety itself degrades adherence — and $380/month is a rational purchase of cognitive peace with a regulator's signature on it. People pay more than that for certainty in far less important domains.
The case for the $119, at full strength
$4,560 a year is not a rounding error — it's the difference between treating and not treating for a large share of cash payers, and an untreated year has its own bill (the prevention data prices it). The compounded lane's risk is real but manageable: a verified 503A with clean licensure in your state, a batch COA showing base semaglutide at potency, and a program that passes the field manual has closed most of the distance the certificate covers — not all of it, and this site never pretends otherwise, but enough that the residual risk versus $4,560/year is a defensible adult trade. The floor's own audit discipline (24-for-24 verified, terms published, exits clean) is exactly what makes the trade calculable rather than hopeful. The audited $119 floor ↗
The lanes between the extremes
This is a cash comparison, so first exhaust the lanes that beat both: a covered copay plus savings card (~$25-class) wins outright — run the coverage test and appeal before choosing between cash options. And note the brand side's own budget lane exists mostly on the tirzepatide shelf ($349-class vials), which reframes some shoppers' question entirely into the molecule choice rather than the manufacturing one.
The four-question sorter
Can any insurance path get you covered brand? Yes → that lane, full stop. Does $380/month change whether you can sustain therapy at all? Yes → the verified compounded floor beats the untreated alternative by every number on this site. Have you verified the pharmacy chain and COA? No → do that before comparing prices, because an unverified $119 isn't cheap, it's unpriced. Is dose-drawing or batch anxiety going to erode your adherence? Yes → the pen's engineering is therapy too, and the $380 is buying outcomes, not vibes. Four honest answers; the verdict writes itself — and it's yours, not ours.
FAQ
Is compounded semaglutide as good as Wegovy?
It intends the same base molecule without the FDA's finished-product review — verified identity, potency, sterility and consistency are the brand's certificates. A verified 503A with a clean COA narrows the gap; it doesn't erase it.
What exactly does the $380/month buy?
FDA-reviewed manufacturing consistency, the trial certificate, a dose-engineered pen that eliminates vial math, and national-scale pharmacovigilance.
Who should pay for brand Wegovy cash?
Patients whose budget clears $499 comfortably, who value certificate-grade certainty, prefer the pen, or whose precision anxiety would tax adherence — and anyone with a prior bad compounding experience.
Who reasonably chooses the compounded floor?
Cash payers for whom $4,560/year decides whether treatment happens at all — after verifying the pharmacy chain, COA, and program integrity per the field manual.
Sources
- NovoCare published self-pay pricing; audited compounded pricing — the open dataset, 2026-08-14.
- FDA compounding framework and finished-product review scope.
- STEP 1, SELECT, FLOW — the certificates at issue.
- FDA compounded-semaglutide communications (salt forms, dosing errors).